These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24260986)

  • 1. Successful desensitization with agalsidase alfa in 2 brothers with Fabry disease.
    Aydin O; Kasapkara CS; Celik GE
    J Investig Allergol Clin Immunol; 2013; 23(5):367-8. PubMed ID: 24260986
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful desensitization to agalsidase beta after anaphylaxis.
    Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
    Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment.
    DuBuske I; Schmidlin K; Bernstein JA
    Ann Allergy Asthma Immunol; 2021 Jan; 126(1):96-98. PubMed ID: 32866621
    [No Abstract]   [Full Text] [Related]  

  • 4. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
    Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
    J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease.
    Hughes DA; Deegan PB; Milligan A; Wright N; Butler LH; Jacobs A; Mehta AB
    Mol Genet Metab; 2013 Jul; 109(3):269-75. PubMed ID: 23702393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on role of agalsidase alfa in management of Fabry disease.
    Ramaswami U
    Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
    Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
    Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
    Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
    [No Abstract]   [Full Text] [Related]  

  • 11. Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance.
    Mougenot P; Lidove O; Caillaud C; Arnaud P; Papo T
    Eur J Clin Pharmacol; 2008 Jun; 64(6):635-9. PubMed ID: 18224310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.
    Tesmoingt C; Lidove O; Reberga A; Thetis M; Ackaert C; Nicaise P; Arnaud P; Papo T
    Br J Clin Pharmacol; 2009 Nov; 68(5):765-9. PubMed ID: 19917001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
    Linthorst GE; Aerts JM
    J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
    Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
    PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of agalsidase alfa in patients with Fabry disease under 7 years.
    Ramaswami U; Parini R; Kampmann C; Beck M
    Acta Paediatr; 2011 Apr; 100(4):605-11. PubMed ID: 21114524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
    Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
    Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.
    Schiffmann R; Askari H; Timmons M; Robinson C; Benko W; Brady RO; Ries M
    J Am Soc Nephrol; 2007 May; 18(5):1576-83. PubMed ID: 17409308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies.
    Tsurumi M; Suzuki S; Hokugo J; Ueda K
    Expert Opin Drug Saf; 2021 May; 20(5):589-601. PubMed ID: 33599146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.